NCT Number: NCT02720354
A Phase I Study of a Novel Tracer for Positron Emission Tomography "PET" Myocardial Perfusion Imaging "MPI"
[11C]-dimethyl-diphenyl ammonium ([11C]-DMDPA) - A Phase I, Open-label, Safety and Tolerability, Radiation Dosimetry, Biodistribution, First-in-Human Study of a Novel 11C-labeled Tracer for Positron Emission Tomography Myocardial Perfusion Imaging
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–40 year
Sex eligibility
Male
Study type
Interventional
Phase
Phase 1
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- body mass index (BMI) between 18.0 and 30.0 kg/m2
- good health
- written informed consent
Exclusion criteria
- smokers
- subject receiving medication
- a blood transfusion in the 4 weeks prior to screening
- positive alcohol blood test
- Subjects who suffer from claustrophobia
- Subjects who have had a clinically significant illness
- Subjects exposed to radiation within 12 months prior to screening
Treatment and study plan
Primary outcomes
-
Measurement of absorbed radiation dose for all target organs in megabecquerel (the activity of a quantity of radioactive material in which one nucleus decays per second).
Time frame: within 80 minutes
Sponsors and collaborators
Lead sponsor
Synektik S.A.
Industry
Collaborators
- European Commission
Registry information
Important dates
- Study start
- 2016
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Mar 25, 2016
- Registry last updated
- Oct 20, 2017
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
CES1 Carriers in the PAPI Study
NCT03188705
Arterial Occlusive Diseases, Arteriosclerosis
Lancaster, Pennsylvania, United States
View Trial DetailsImpact of Cardiac Rehabilitation on Patient Outcomes
NCT07468955
Arterial Occlusive Diseases, Arteriosclerosis
Kütahya, Center, Turkey (Türkiye)
View Trial DetailsA Sugar-Sweetened Beverage Reduction Intervention for Native American Men
NCT06029517
Arterial Occlusive Diseases, Arteriosclerosis
Buffalo, New York, United States
View Trial DetailsSafety and Effectiveness of Agent Paclitaxel-Coated PTCA Balloon Catheter. (AGENT Japan SV)
NCT04058990
Arterial Occlusive Diseases, Arteriosclerosis
Kitakyushu, Fukuoka, Japan
View Trial Details